Company profile RNXT
Google Trends for RenovoRx
Q4 +68.1% YoY, +317.2% QoQ | Q1 +20.7% YoY, +10.7% QoQ | Correlation: nan
After 38 days of this quarter the interest is at 56.0. Based on that we can calculate that during remaining 53 days it will total up to 134.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 63 | 0 -100.0% QoQ | 83 inf% QoQ | 64 -22.9% QoQ |
| 2020 | 39 -38.1% YoY -39.1% QoQ | 23 inf% YoY -41.0% QoQ | 30 -63.9% YoY 30.4% QoQ | 38 -40.6% YoY 26.7% QoQ |
| 2021 | 62 59.0% YoY 63.2% QoQ | 81 252.2% YoY 30.6% QoQ | 263 776.7% YoY 224.7% QoQ | 148 289.5% YoY -43.7% QoQ |
| 2022 | 197 217.7% YoY 33.1% QoQ | 98 21.0% YoY -50.3% QoQ | 60 -77.2% YoY -38.8% QoQ | 72 -51.4% YoY 20.0% QoQ |
| 2023 | 111 -43.7% YoY 54.2% QoQ | 27 -72.4% YoY -75.7% QoQ | 29 -51.7% YoY 7.4% QoQ | 121 68.1% YoY 317.2% QoQ |
| 2024 | 56 -49.5% YoY -53.7% QoQ | - | - | - |
The average 5 years interest of RenovoRx was 6.4 per week. The last year interest of RenovoRx compared to the last 5 years has changed by -7.19%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 32.0%.
There is not enough data for RenovoRx RenovoGem to provide analysis
There is not enough data for RenovoRx RenovoGem to provide correlation calculation
There is not enough data for RenovoRx RenovoGem to provide analysis
There is not enough data for RenovoCath to provide analysis
There is not enough data for RenovoCath to provide correlation calculation
There is not enough data for RenovoCath to provide analysis
After 39 days of this quarter the interest is at 186.0. Based on that we can calculate that during remaining 52 days it will total up to 434.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 400 | 571 42.8% QoQ | 470 -17.7% QoQ | 565 20.2% QoQ |
| 2020 | 495 23.8% YoY -12.4% QoQ | 353 -38.2% YoY -28.7% QoQ | 423 -10.0% YoY 19.8% QoQ | 412 -27.1% YoY -2.6% QoQ |
| 2021 | 399 -19.4% YoY -3.2% QoQ | 430 21.8% YoY 7.8% QoQ | 555 31.2% YoY 29.1% QoQ | 450 9.2% YoY -18.9% QoQ |
| 2022 | 438 9.8% YoY -2.7% QoQ | 521 21.2% YoY 18.9% QoQ | 446 -19.6% YoY -14.4% QoQ | 402 -10.7% YoY -9.9% QoQ |
| 2023 | 428 -2.3% YoY 6.5% QoQ | 489 -6.1% YoY 14.3% QoQ | 473 6.1% YoY -3.3% QoQ | 472 17.4% YoY -0.2% QoQ |
| 2024 | 186 -56.5% YoY -60.6% QoQ | - | - | - |
The average 5 years interest of pancreatic cancer treatment was 35.93 per week. The last year interest of pancreatic cancer treatment compared to the last 5 years has changed by -0.92%. The interest for pancreatic cancer treatment is seasonal. The last year interest is quite lower compared to 5 years ago. It has decreased by -17.09%.
There is not enough data for clinical-stage biopharmaceutical company to provide analysis
There is not enough data for clinical-stage biopharmaceutical company to provide correlation calculation
There is not enough data for clinical-stage biopharmaceutical company to provide analysis
After 34 days of this quarter the interest is at 38.0. Based on that we can calculate that during remaining 58 days it will total up to 103.0. solid tumors therapy expected interest is significantly lower compared to previous quarter (-56.5%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 128 |
| 2019 | 65 -49.2% QoQ | 43 -33.8% QoQ | 71 65.1% QoQ | 57 -55.5% YoY -19.7% QoQ |
| 2020 | 78 20.0% YoY 36.8% QoQ | 92 114.0% YoY 17.9% QoQ | 87 22.5% YoY -5.4% QoQ | 198 247.4% YoY 127.6% QoQ |
| 2021 | 184 135.9% YoY -7.1% QoQ | 201 118.5% YoY 9.2% QoQ | 169 94.3% YoY -15.9% QoQ | 87 -56.1% YoY -48.5% QoQ |
| 2022 | 104 -43.5% YoY 19.5% QoQ | 64 -68.2% YoY -38.5% QoQ | 252 49.1% YoY 293.8% QoQ | 159 82.8% YoY -36.9% QoQ |
| 2023 | 302 190.4% YoY 89.9% QoQ | 274 328.1% YoY -9.3% QoQ | 237 -6.0% YoY -13.5% QoQ | 38 -76.1% YoY -84.0% QoQ |
The average 5 years interest of solid tumors therapy was 11.07 per week. The last year interest of solid tumors therapy compared to the last 5 years has changed by 69.92%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 218.81%.
There is not enough data for intra-arterial gemcitabine to provide analysis
There is not enough data for intra-arterial gemcitabine to provide correlation calculation
There is not enough data for intra-arterial gemcitabine to provide analysis
There is not enough data for research collaboration with Imugene Limited to provide analysis
There is not enough data for research collaboration with Imugene Limited to provide correlation calculation
There is not enough data for research collaboration with Imugene Limited to provide analysis
After 38 days of this quarter the interest is at 14.0. Based on that we can calculate that during remaining 53 days it will total up to 34.0. oncolytic virus therapy expected interest is significantly lower compared to previous quarter (-83.9%) and same quarter last year (-73.4%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 97 | 151 55.7% QoQ | 108 -28.5% QoQ | 105 -2.8% QoQ |
| 2020 | 69 -28.9% YoY -34.3% QoQ | 298 97.4% YoY 331.9% QoQ | 70 -35.2% YoY -76.5% QoQ | 106 1.0% YoY 51.4% QoQ |
| 2021 | 52 -24.6% YoY -50.9% QoQ | 74 -75.2% YoY 42.3% QoQ | 196 180.0% YoY 164.9% QoQ | 210 98.1% YoY 7.1% QoQ |
| 2022 | 169 225.0% YoY -19.5% QoQ | 244 229.7% YoY 44.4% QoQ | 59 -69.9% YoY -75.8% QoQ | 137 -34.8% YoY 132.2% QoQ |
| 2023 | 128 -24.3% YoY -6.6% QoQ | 214 -12.3% YoY 67.2% QoQ | 175 196.6% YoY -18.2% QoQ | 211 54.0% YoY 20.6% QoQ |
| 2024 | 14 -89.1% YoY -93.4% QoQ | - | - | - |
The average 5 years interest of oncolytic virus therapy was 11.1 per week. The last year interest of oncolytic virus therapy compared to the last 5 years has changed by 23.87%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 55.02%.
There is not enough data for difficult-to-access tumors. to provide analysis
There is not enough data for difficult-to-access tumors. to provide correlation calculation
There is not enough data for difficult-to-access tumors. to provide analysis